Moleculin Biotech vs Transcode Therapeutics
MBRX and RNAZ side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MBRX and RNAZ compare
Moleculin Biotech is the larger company, worth 102 times as much as Transcode Therapeutics ($139M against $1.4M).
Transcode Therapeutics scores higher on the StockData Score (5 against 4 for Moleculin Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MBRX | RNAZ |
|---|---|---|
| Size and price | ||
| Market cap | $139M | $1.4M |
| Share price | $7.14 | $1.35 |
| Change, 1 year | −96.9% | −84.0% |
| Change, 5 years | −100.0% | −100.0% |
| Beta (5Y) | −1.16 | 0.63 |
| Employees | 150K | 12 |
| StockData Score | ||
| Total score | 4 | 5 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 12.0× | – |
| Profitability | ||
| Return on equity | −524% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 0.94 | 1.97 (better) |
| Altman Z-score | −10.81 | −2.01 (better) |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 0.05% | 3.3% |
| Held by insiders | 20.2% | – |
| Short interest, % of float | 0.35% | – |
Go deeper
- MBRX stock overview
- MBRX income statement
- MBRX valuation and score
- RNAZ stock overview
- RNAZ income statement
- RNAZ valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.